TNSN00169A1 - Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions pharmaceutiques les contenant - Google Patents
Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions pharmaceutiques les contenantInfo
- Publication number
- TNSN00169A1 TNSN00169A1 TNTNSN00169A TNSN00169A TNSN00169A1 TN SN00169 A1 TNSN00169 A1 TN SN00169A1 TN TNSN00169 A TNTNSN00169 A TN TNSN00169A TN SN00169 A TNSN00169 A TN SN00169A TN SN00169 A1 TNSN00169 A1 TN SN00169A1
- Authority
- TN
- Tunisia
- Prior art keywords
- triones
- pyrimidine
- pharmaceutical compositions
- compositions containing
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRESENTE INVENTION CONCERNE DES INHIBITEURS DE METALLOPROTEINASES, CONSISTANT EN PYRIMIDINE-2,4,6- TRIONES DE FORMULE I :DANS LAQUELLE X,Y,AR1,Z,R1,R2 ET R3 REPRESENTENT DIVERS RADICAUX . ELLE CONCERNE EGALEMENT DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEUR UTILISATION POUR LA FABRICATION DE MEDICAMENTS. APPLICATION : METHODES POUR LE TRAITEMENT DE DIVERSES MALADIES, NOTAMMENT DE L'INFLAMMATION ET DU CANCER.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14854799P | 1999-08-12 | 1999-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN00169A1 true TNSN00169A1 (fr) | 2005-11-10 |
Family
ID=22526231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNTNSN00169A TNSN00169A1 (fr) | 1999-08-12 | 2000-08-11 | Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions pharmaceutiques les contenant |
Country Status (41)
| Country | Link |
|---|---|
| US (1) | US6579982B1 (fr) |
| EP (1) | EP1202974B1 (fr) |
| JP (1) | JP2003507371A (fr) |
| KR (2) | KR20040073608A (fr) |
| CN (1) | CN1156454C (fr) |
| AR (1) | AR025091A1 (fr) |
| AT (1) | ATE309224T1 (fr) |
| AU (1) | AU773751B2 (fr) |
| BG (1) | BG106406A (fr) |
| BR (1) | BR0013081A (fr) |
| CA (1) | CA2381551A1 (fr) |
| CO (1) | CO5180629A1 (fr) |
| CR (1) | CR6565A (fr) |
| CZ (1) | CZ2002355A3 (fr) |
| DE (1) | DE60023903D1 (fr) |
| EA (1) | EA004680B1 (fr) |
| EC (1) | ECSP003610A (fr) |
| EE (1) | EE200200069A (fr) |
| GE (1) | GEP20053424B (fr) |
| GT (1) | GT200000137A (fr) |
| HK (1) | HK1045995B (fr) |
| HN (1) | HN2000000137A (fr) |
| HR (1) | HRP20020129A2 (fr) |
| HU (1) | HUP0202501A3 (fr) |
| IL (1) | IL148035A0 (fr) |
| IS (1) | IS6248A (fr) |
| MA (1) | MA26812A1 (fr) |
| MX (1) | MXPA02001561A (fr) |
| NO (1) | NO20020662L (fr) |
| NZ (1) | NZ516562A (fr) |
| OA (1) | OA12000A (fr) |
| PA (1) | PA8498701A1 (fr) |
| PE (1) | PE20010491A1 (fr) |
| PL (1) | PL353871A1 (fr) |
| SK (1) | SK1652002A3 (fr) |
| TN (1) | TNSN00169A1 (fr) |
| TR (1) | TR200200381T2 (fr) |
| UY (1) | UY26285A1 (fr) |
| WO (1) | WO2001012611A1 (fr) |
| YU (1) | YU6602A (fr) |
| ZA (1) | ZA200201070B (fr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| IL154946A0 (en) * | 2000-10-26 | 2003-10-31 | Pfizer Prod Inc | Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| EP1332146A2 (fr) * | 2000-10-26 | 2003-08-06 | Pfizer Products Inc. | Inhibiteurs de metalloproteinase spiro-pyrimidine-2,4,6-trione |
| US6841671B2 (en) | 2000-10-26 | 2005-01-11 | Pfizer Inc. | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| DOP2002000333A (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz |
| PA8539501A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
| CA2433075A1 (fr) | 2001-02-14 | 2002-08-22 | Michael William Wilson | Benzo-thiadiazines inhibitrices des metalloproteinases matricielles |
| DE60236851D1 (en) | 2001-02-14 | 2010-08-12 | Warner Lambert Co | Pyrimidinmatrixmetalloproteinaseinhibitoren |
| DOP2002000332A (es) | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Inhibidores de piridina de metaloproteinasas de la matriz |
| US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
| JP2003081838A (ja) * | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | グルコサミン製剤 |
| CA2462442A1 (fr) | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Inhibiteurs de metalloproteinase matricielle (mmp) a base d'alkyne |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| WO2003053940A1 (fr) | 2001-12-20 | 2003-07-03 | Bristol-Myers Squibb Company | Derives d'acide barbiturique utilises comme inhibiteurs de l'enzyme de conversion du tnf-$g(a) (tace) et/ou de metalloproteinases matricielles |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| AU2003220401A1 (en) | 2002-03-18 | 2003-10-08 | Bristol-Myers Squibb Company | Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases |
| NI200300045A (es) | 2002-04-26 | 2005-07-08 | Pfizer Prod Inc | Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa. |
| BR0309281A (pt) * | 2002-04-26 | 2005-02-22 | Pfizer Prod Inc | Triaril-oxi-espiro-pirimidino-2,4,6-trionas inibidoras de metaloproteinases |
| DE60302150D1 (en) * | 2002-04-26 | 2005-12-08 | Pfizer Prod Inc | N-substituiete heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trion metalloproteinase inhibitoren |
| CA2483500A1 (fr) * | 2002-04-26 | 2003-11-06 | Pfizer Products Inc. | Inhibiteurs de metalloproteinase a base de pyrimidine-2, 4, 6-trione |
| EP1537098A1 (fr) | 2002-08-13 | 2005-06-08 | Warner-Lambert Company LLC | Derives monocycliques en tant qu'inhibiteurs de metalloproteinases matricielles |
| WO2004014908A1 (fr) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Inhibiteurs de metalloproteinases heterobicycliques |
| EP1553949B1 (fr) | 2002-08-13 | 2007-04-18 | Warner-Lambert Company LLC | Derives de pyrimidine 2,4-diones, utilises comme inhibiteurs de metalloproteinase matricielle |
| WO2004014923A1 (fr) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Inhibiteurs de metalloprotease bicycliques condenses avec la pyrimidinone |
| PA8578101A1 (es) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
| AU2003253186A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
| CA2497658A1 (fr) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Derives de chromone inhibiteurs de metalloproteinase de matrice |
| WO2004014378A1 (fr) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Derives de 3-isoquinolinone utilises comme inhibiteurs de metalloprotease de matrice |
| AU2003249531A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
| WO2004084903A1 (fr) * | 2003-03-27 | 2004-10-07 | F. Hoffmann-La Roche Ag | Utilisation d'une trioxopyrimidine pour le traitement et la prevention de l'angiogenese pathologique oculaire |
| WO2004084902A1 (fr) * | 2003-03-28 | 2004-10-07 | F. Hoffmann-La Roche Ag | Utilisation d'une trioxopyrimidine dans le traitement de lesions chroniques |
| WO2004089294A2 (fr) | 2003-04-04 | 2004-10-21 | Incyte Corporation | Compositions, procedes et kits relatifs au clivage de her-2 |
| US20050107350A1 (en) * | 2003-08-22 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith |
| WO2012014109A1 (fr) | 2010-07-30 | 2012-02-02 | Ranbaxy Laboratories Limited | Sulfamides hétérocycliques servant d'inhibiteurs de synthétase d'arn de transfert, destinés à être utilisés en tant qu'agents antibactériens |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| US20150366275A1 (en) * | 2014-06-19 | 2015-12-24 | Gyula Cserfoi | Wearable Signaling Device |
| GB201705255D0 (en) | 2017-03-31 | 2017-05-17 | Univ I Tromsø - Norges Arktiske Univ | Bioactive cyclic compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ62799A3 (cs) * | 1996-08-28 | 1999-07-14 | The Procter & Gamble Company | Heterocyklické metaloproteázové inhibitory |
| WO1998058925A1 (fr) * | 1997-06-21 | 1998-12-30 | Roche Diagnostics Gmbh | Derives d'acide barbiturique dotes d'une activite antimetastatique et anitumorale |
-
2000
- 2000-07-20 HN HN2000000137A patent/HN2000000137A/es unknown
- 2000-07-20 PA PA20008498701A patent/PA8498701A1/es unknown
- 2000-08-03 MX MXPA02001561A patent/MXPA02001561A/es active IP Right Grant
- 2000-08-03 YU YU6602A patent/YU6602A/sh unknown
- 2000-08-03 IL IL14803500A patent/IL148035A0/xx unknown
- 2000-08-03 EA EA200200058A patent/EA004680B1/ru not_active IP Right Cessation
- 2000-08-03 BR BR0013081-8A patent/BR0013081A/pt not_active IP Right Cessation
- 2000-08-03 KR KR10-2004-7011899A patent/KR20040073608A/ko not_active Application Discontinuation
- 2000-08-03 PL PL00353871A patent/PL353871A1/xx not_active Application Discontinuation
- 2000-08-03 CZ CZ2002355A patent/CZ2002355A3/cs unknown
- 2000-08-03 JP JP2001517509A patent/JP2003507371A/ja active Pending
- 2000-08-03 AU AU60105/00A patent/AU773751B2/en not_active Ceased
- 2000-08-03 NZ NZ516562A patent/NZ516562A/xx unknown
- 2000-08-03 WO PCT/IB2000/001090 patent/WO2001012611A1/fr active IP Right Grant
- 2000-08-03 SK SK165-2002A patent/SK1652002A3/sk unknown
- 2000-08-03 GE GE4688A patent/GEP20053424B/en unknown
- 2000-08-03 AT AT00946235T patent/ATE309224T1/de not_active IP Right Cessation
- 2000-08-03 CA CA002381551A patent/CA2381551A1/fr not_active Abandoned
- 2000-08-03 DE DE60023903T patent/DE60023903D1/de not_active Expired - Lifetime
- 2000-08-03 HU HU0202501A patent/HUP0202501A3/hu unknown
- 2000-08-03 EP EP00946235A patent/EP1202974B1/fr not_active Expired - Lifetime
- 2000-08-03 OA OA1200200030A patent/OA12000A/en unknown
- 2000-08-03 TR TR2002/00381T patent/TR200200381T2/xx unknown
- 2000-08-03 EE EEP200200069A patent/EE200200069A/xx unknown
- 2000-08-03 KR KR1020027001880A patent/KR20020047119A/ko active IP Right Grant
- 2000-08-03 CN CNB008113920A patent/CN1156454C/zh not_active Expired - Fee Related
- 2000-08-04 CO CO00058849A patent/CO5180629A1/es not_active Application Discontinuation
- 2000-08-09 UY UY26285A patent/UY26285A1/es not_active Application Discontinuation
- 2000-08-09 US US09/635,156 patent/US6579982B1/en not_active Expired - Fee Related
- 2000-08-09 EC EC2000003610A patent/ECSP003610A/es unknown
- 2000-08-10 PE PE2000000811A patent/PE20010491A1/es not_active Application Discontinuation
- 2000-08-10 GT GT200000137A patent/GT200000137A/es unknown
- 2000-08-10 AR ARP000104130A patent/AR025091A1/es unknown
- 2000-08-11 TN TNTNSN00169A patent/TNSN00169A1/fr unknown
-
2002
- 2002-01-25 IS IS6248A patent/IS6248A/is unknown
- 2002-01-29 CR CR6565A patent/CR6565A/es not_active Application Discontinuation
- 2002-02-07 MA MA26512A patent/MA26812A1/fr unknown
- 2002-02-07 ZA ZA200201070A patent/ZA200201070B/en unknown
- 2002-02-11 NO NO20020662A patent/NO20020662L/no not_active Application Discontinuation
- 2002-02-12 HR HR20020129A patent/HRP20020129A2/xx not_active Application Discontinuation
- 2002-02-12 BG BG06406A patent/BG106406A/xx unknown
- 2002-10-17 HK HK02107534.6A patent/HK1045995B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN00169A1 (fr) | Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions pharmaceutiques les contenant | |
| TNSN98017A1 (fr) | Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| TNSN01149A1 (fr) | Spiro-pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions les contenant. | |
| TNSN99073A1 (fr) | Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN99006A1 (fr) | 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN00121A1 (fr) | Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN99053A1 (fr) | Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant | |
| TNSN99055A1 (fr) | Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN98022A1 (fr) | DERIVES DE N-HYDROXY-β-SULFONYLPROPIONAMIDE, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. | |
| TNSN00036A1 (fr) | Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| TNSN98150A1 (fr) | Derives d'acides aryloxyarylsulfonylaminohydroxamiques ; procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN01019A1 (fr) | Pyrimidinecarboxamides utiles comme inhibiteurs d'iso-ezymes pde4, et compositions les contenant | |
| TNSN01114A1 (fr) | Derives d'imidazole nouveaux et compositions les contenant | |
| TNSN01047A1 (fr) | Procede pour la preparation de derives de piperazine nouveaux | |
| TNSN00028A1 (fr) | Derives de quinoleine -2-one a substituant heteroaryle nouveaux procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| TNSN98019A1 (fr) | Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| TNSN98045A1 (fr) | Derives de nicotinamide nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| TNSN00065A1 (fr) | Derives nouveaux de pyrimidine inhibiteurs de sorbitol- deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant. | |
| TNSN99171A1 (fr) | 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN99155A1 (fr) | 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN97198A1 (fr) | Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant | |
| TNSN99126A1 (fr) | Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN01020A1 (fr) | Derives heterocycliques benzocondenses de nicotinamide, et compositions les contenant | |
| TNSN02009A1 (fr) | Pyrimidinones bicycliques condensees nouvelles, inhibitrices de mmp, et compositions les contenant. | |
| TNSN99172A1 (fr) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant |